Receptor tyrosine kinases in sinonasal undifferentiated carcinomas - Evaluation for EGFR, c-KIT, and HER2/neu expression

Head and Neck

Volumn 31, Issue 7, 2009, Pages 919-927

  Chernock, Rebecca D ^a   Perry, Arie ^a   Pfeifer, John D ^a   Holden, Joseph A ^b   Lewis Jr , James S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Activating mutations; c KIT; Epidermal growth factor receptor; HER2 neu; Sinonasal undifferentiated carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME 4; CLINICAL ARTICLE; CLINICAL EVALUATION; DNA DENATURATION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NOSE CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SINONASAL UNDIFFERENTIATED CARCINOMA; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; PARANASAL SINUS NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES;

EID: 67650505626     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21061     Document Type: Article

References (49)

1. Frierson HF. Sinonasal undifferentiated carcinoma. In: Barnes L, Eveson JW, Reichart PA, Sidransky D, editors. Pathology and genetics of head and neck tumours (World Health Organization classification of tumours). Lyon, France: International Agency for Research on Cancer; 2005. p 19.
2. Ejaz A, Wenig B. Sinonasal undifferentiated carcinoma. Clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol 2005;12:134-143.
3. Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck 2004;26:435-441. (Pubitemid 38569202)
4. Mendenhall WM, Mendenhall CM, Riggs CE, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. Am J Clin Oncol 2006;29:27-31.
5. Kim BS, Vongtama R, Julliard G. Sinonassal undifferentiated carcinoma: case series and literature review. Am J Otolaryngol 2004;25:162-166. (Pubitemid 38656628)
6. Gorelick J, Ross D, Marentette L, Blaivas M. Sinonasal undifferentiated carcinoma: case series and review of the literature. Neurosurgery 2000;47:750-755. (Pubitemid 32044722)
7. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411:355-365.
8. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996;32A:2070-2074. (Pubitemid 26419455)
9. Messa C, Russo F, Caruso MG, Leo AD. TGF-alpha and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998;37:285-289. (Pubitemid 28307854)
10. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
11. Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfled JL, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-522. (Pubitemid 27211827)
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogenes. Science 1987;235:177-182. (Pubitemid 17231334)
13. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349. (Pubitemid 46621810)
15. Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 2004;122:206-216. (Pubitemid 38971353)
16. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003;49:853-860. (Pubitemid 36623462)
17. Perry A, Fuller C, Banerjee R, Brat DJ, Scheithauer BW. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 2003;8:a1-a9. (Pubitemid 39069937)
18. Rajaram V, Leuthardt EC, Singh PK, et al. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Mod Pathol 2004;17:9-14.
19. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005;97:643-655. (Pubitemid 40812628)
20. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-1675. (Pubitemid 32708634)
21. Antonescu CR, Sommoer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337. (Pubitemid 37082727)
22. Gomes AL, Gouveia A, Capellinha AF, et al. Molecular alterations of KIT and PDGFRA in GISTs. An evaluation of a Portuguese series. J Clin Pathol 2008;61:203-208. (Pubitemid 351218881)
23. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 2000;157:1091-1095. (Pubitemid 30757930)
24. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795. (Pubitemid 30626936)
25. Ma Y, Zeng S, Metclafe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-1744. (Pubitemid 34533049)
26. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-5058. (Pubitemid 32769795)
27. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710. (Pubitemid 36159485)
28. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to Imatinib. J Clin Oncol 2005;23:5357-5364. (Pubitemid 46206989)
29. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12:956-960. (Pubitemid 29485269)
30. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 1995;177:253-258.
31. Tickoo SK, Hutchinson B, Bacik J, et al. Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. Int J Surg Pathol 2002;10:23-32. (Pubitemid 34245955)
32. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cell of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994;424:135-141. (Pubitemid 24105555)
33. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998;29:498-504. (Pubitemid 28213470)
34. Schwartz S, Heinecke A, Zimmerman M, et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999;34:85-94. (Pubitemid 29248662)
35. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 2004;121:878-883. (Pubitemid 38669283)
36. Araki K, Ishii G, Yokose T, et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40:173-180. (Pubitemid 36438718)
37. Burger H, den Bakker MA, Kros JM, et al. Activating mutations in c-kit and PDGFRA are exclusively found in gastrointestinal stromal tumors and not other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005;4:1270-1274.
38. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57. (Pubitemid 41702622)
39. Janku F, Novotny J, Julis I, et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 2005;15:251-256. (Pubitemid 41127460)
40. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. BRAF and c-kit copy number in mutation-positive malignant melanoma. Hum Pathol 2006;37:520-527.
41. Gil Z, Orr-Urtreger A, Voskoboinik N, et al. Cytogenetic analysis of sinonasal carcinomas. Otolaryngol Head Neck Surg 2006;34:654-660.
42. Kawakami T, Soma Y, Kawa Y, et al. Transforming growth factor b1 regulates melanocyte proliferation and differentiation in mouse neural crest cells via stem cell factor/KIT signaling. J Invest Dermatol 2002;118:471-478. (Pubitemid 34227164)
43. Marshall CJ, Sinclair JC, Thrasher AJ, Kinnon C. Bone morphogenetic protein 4 modulates c-Kit expression and differentiation potential in murine embryonic aortagonad-mesonephros haematopoiesis in vitro. Br J Haematol 2007;139:321-330. (Pubitemid 47493096)
44. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811-1816. (Pubitemid 41631245)
45. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. A phase II clinical trial. Cancer 2005;103:2128-2131.
46. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005;23:585-590. (Pubitemid 46224236)
47. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck 2005;27:1022-1027. (Pubitemid 41705578)
48. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib mesylate can induce objective response in progressing highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 2005;23:6271-6273. (Pubitemid 46300262)
49. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 2004;26:829-831. (Pubitemid 39159307)